Re:23andMe to share customer gene data with GlaxoSmithKline ...
by raven105x on Wednesday December 18, 2019 @12:26AM
(#21822089)
Saving people is extremely profitable - curing, however, is anything but.
[ Parent
| on HN ]
Re:23andMe to share customer gene data with GlaxoSmithKline ...
by roenxi on Wednesday December 18, 2019 @01:45AM
(#21822445)
Curing people is still profitable. If you are competing with an incumbent who only treats symptoms you can claim their business by curing patients.
Unless somehow it were possible to gain a monopoly on curing people, which is plausible but fundamentally not the responsibility of the researchers.
Re:23andMe to share customer gene data with GlaxoSmithKline ...
by kevingadd on Wednesday December 18, 2019 @01:49AM
(#21822472)
Have you heard of patents? For-profit pharmaceutical companies use them to establish a monopoly on drugs they develop.
Re:23andMe to share customer gene data with GlaxoSmithKline ...
by kungito on Wednesday December 18, 2019 @06:13AM
(#21823786)
Patents last 20 years, humanity existed for thousands. We can wait 100 more years for cures if it's the optimal way
Re:23andMe to share customer gene data with GlaxoSmithKline ...
by autoexec on Wednesday December 18, 2019 @06:48PM
(#21830712)
The drug companies have a solution to patent limits called "evergreening" where once a patent is about to expire they make a very slight modification to the formula, pump massive amounts of cash into marketing it as "new and better" even when there are little to no benefits over the old formula. Doctors are easily bribed or mislead into prescribing the expensive new formula over generics and drug companies can continue to make large profits on old drugs instead of innovating.